Trial
NCT03169738
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
ImmunityBio, Inc.
Collaborators
—
Condition
Non-small Cell Lung Cancer
Intervention
avelumab
Why stopped
Trial not initiated
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-21